

1 **Multi-analyte proteomic analysis identifies blood-based neuroinflammation,**
2 **cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease**

3 Xuemei Zeng¹ · Tara K. Lafferty¹ · Anuradha Sehrawat¹ · Yijun Chen² · Pamela C. L. Ferreira¹ ·
4 Bruna Bellaver¹ · Guilherme Povala¹ · M. Ilyas Kamboh³ · William E. Klunk¹ · Ann D. Cohen¹ ·
5 Oscar L. Lopez⁴ · Milos D. Ikonovic^{1,4,5} · Tharick A. Pascoal¹ · Mary Ganguli^{1,4,6} · Victor L.
6 Villemagne¹ · Beth E. Snitz⁴ · Thomas K. Karikari^{1*}

7

8 ¹ Department of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street,
9 Pittsburgh, PA 15213, USA

10 ² Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15213, USA

11 ³ Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh,
12 PA 15213, USA

13 ⁴ Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213,
14 USA

15 ⁵ Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA

16 ⁶ Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh,
17 Pennsylvania, USA

18

19 *Corresponding author. Department of Psychiatry, School of Medicine, University of Pittsburgh,
20 Pittsburgh 15213, PA, USA. Email: Karikaritk@upmc.edu

21 **Abstract**

22 **Background:** Blood-based biomarkers are gaining grounds for Alzheimer's disease (AD)
23 detection. However, two key obstacles need to be addressed: the lack of methods for multi-
24 analyte assessments and the need for markers of neuroinflammation, vascular, and synaptic
25 dysfunction. Here, we evaluated a novel multi-analyte biomarker platform, NULISaseq CNS
26 disease panel, a multiplex NUcleic acid-linked Immuno-Sandwich Assay (NULISA) targeting
27 ~120 analytes, including classical AD biomarkers and key proteins defining various disease
28 hallmarks.

29 **Methods:** The NULISaseq panel was applied to 176 plasma samples from the MYHAT-NI
30 cohort of cognitively normal participants from an economically underserved region in Western
31 Pennsylvania. Classical AD biomarkers, including p-tau181, p-tau217, p-tau231, GFAP, NEFL,
32 A β 40, and A β 42, were also measured using Single Molecule Array (Simoa). Amyloid pathology,
33 tau pathology, and neurodegeneration were evaluated with [11C] PiB PET, [18F]AV-1451 PET,
34 and MRI, respectively. Linear mixed models were used to examine cross-sectional and
35 Wilcoxon rank sum tests for longitudinal associations between NULISA biomarkers and AD
36 pathologies. Spearman correlations were used to compare NULISA and Simoa.

37 **Results:** NULISA concurrently measured 116 plasma biomarkers with good technical
38 performance, and good correlation with Simoa measures. Cross-sectionally, p-tau217 was the
39 top hit to identify A β pathology, with age, sex, and *APOE* genotype-adjusted AUC of 0.930
40 (95%CI: 0.878-0.983). Fourteen markers were significantly decreased in A β -PET+ participants,
41 including TIMP3, which regulates brain A β production, the neurotrophic factor BDNF, the energy
42 metabolism marker MDH1, and several cytokines. Longitudinally, FGF2, IL4, and IL9 exhibited
43 A β PET-dependent yearly increases in A β -PET+ participants. Markers with tau PET-dependent
44 longitudinal changes included the microglial activation marker CHIT1, the reactive astrogliosis
45 marker CHI3L1, the synaptic protein NPTX1, and the cerebrovascular markers PGF, PDGFRB,

46 and VEFGA; all previously linked to AD but only reliably measured in cerebrospinal fluid.
47 SQSTM1, the autophagosome cargo protein, exhibited a significant association with
48 neurodegeneration status after adjusting age, sex, and *APOE* ϵ 4 genotype.

49 **Conclusions:** Together, our results demonstrate the feasibility and potential of immunoassay-
50 based multiplexing to provide a comprehensive view of AD-associated proteomic changes.
51 Further validation of the identified inflammation, synaptic, and vascular markers will be
52 important for establishing disease state markers in asymptomatic AD.

53 **Keywords**

54 Preclinical Alzheimer's disease; plasma biomarkers; proteomics; amyloid pathology; tau
55 pathology; neurodegeneration; NUcleic acid-Linked Immuno-Sandwich Assay (NULISA);
56 NULISA with next-generation sequencing readout (NULISAseq).

57

58 **Background**

59 The draft revision of the amyloid/tau/neurodegeneration (AT(N)) research framework
60 emphasizes the multifaceted nature of Alzheimer's disease (AD), involving diverse brain
61 pathologies and physiological processes [1]. In addition to A (β -amyloid deposition), T
62 (pathologic tau), and N (neurodegeneration) categories, which were included in the 2018 update
63 [2], the proposed upcoming revision recommends biomarker assessments for inflammation (I)
64 as well as mixed pathologies such as vascular (V) pathology and synucleinopathy (S).
65 Furthermore, alteration of synapses can occur early in the AD continuum, even before overt
66 neurodegeneration, making the examination of synaptic markers important in preclinical AD [3-
67 5]. This new framework necessitates a diverse set of biomarkers for more accurate diagnosis,
68 prognosis, clinical management, and development/evaluation of therapies. Analyses of multiple
69 biomarkers integrated into a single test can enhance efficiency, reduce analytical errors, and

70 save on specimen volume. However, multi-analyte assays that provide concurrent information
71 on A, T, and N processes are lacking, let alone those that concomitantly include I, V, and S
72 biomarkers. In fact, glial fibrillary acidic protein (GFAP) is the only marker listed under I, while V
73 has no entry in terms of biofluid biomarkers recommended in the draft revision of the research
74 and diagnostic framework [1].

75 Previous analyses of cerebrospinal fluid (CSF) implicated associations of several inflammatory,
76 vascular, and synaptic function proteins with amyloid-beta ($A\beta$) and tau pathologies in AD.
77 Regarding neuroinflammation, the astrocytic protein chitinase-3 like-protein-1 (CHI3L1), also
78 known as YKL-40, has been shown to associate preferentially with tau pathology, while GFAP, a
79 different astrocytic protein, was more involved with $A\beta$ plaque pathology [6-9]. CSF levels of
80 soluble TREM2, a transmembrane receptor protein predominantly expressed by microglia cells,
81 were increased in AD and associated with tau-dependent neurodegeneration and cognitive
82 decline [10-13]. Levels of TREM1, another microglial transmembrane protein, were also shown
83 to increase in AD dementia compared with cognitively unimpaired controls and those with mild
84 cognitive impairment (MCI) [14]. In addition, multiple interleukins (ILs) in CSF were associated
85 with $A\beta$ and tau pathology, as well as cognitive decline [15-20]. Similarly, several CSF markers
86 of cerebrovascular integrity, such as sPDGFRB (soluble platelet-derived growth factor receptor
87 β), ICAM1, VCAM1, and VEGFs, synaptic markers such as NPTX and NRG1, have been linked
88 to AD and cognitive decline [18, 21-28]. High α -synuclein seed amplification assay positivity has
89 been found in AD and is associated with atypical clinical manifestation [29].

90 A major challenge in the AD biomarker field is the difficulty in accurately measuring the
91 aforementioned neuroinflammation, cerebrovascular, and synaptic protein markers in blood
92 samples to give reliable performances as shown for their CSF counterparts. The development of
93 blood-based assays for these biomarkers has been greatly impeded by several factors,
94 including interference from the extremely complex blood proteome, low abundance of the target

95 analytes, and signal attenuation by unwanted signal from peripheral sources [30, 31]. For
96 example, assays for synaptic markers including NRG1 give good analytical signals in plasma
97 but without the corresponding good biomarker performance as shown in CSF [32, 33].

98 Recently, a highly multiplexed immunoassay capable of measuring classical AT(N) biomarkers
99 alongside multiple I, V, and S biomarkers in plasma has been described [34]. Known as the
100 NULISAseq CNS disease panel, this assay employs an innovative automated technology called
101 Nucleic acid-Linked Immuno-Sandwich Assay (NULISA). Coupling NULISA with next-generation
102 sequencing readout (NULISAseq) allows detection of hundreds of proteins with attomolar
103 sensitivity and an ultra-broad dynamic range [34]. The NULISAseq CNS panel consists of ~120
104 protein targets covering the eight pathological hallmarks that define neurodegenerative
105 diseases: namely, pathological protein aggregation, synaptic and neuronal network dysfunction,
106 aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA
107 defects, inflammation, and neuronal cell death [35].

108 This study had a three-fold aim. Our first aim was to evaluate the technical performance of the
109 NULISAseq CNS disease panel. For classical AT(N) biomarkers (e.g., p-tau181, p-tau217, p-
110 tau231, A β 40, A β 42, GFAP, and neurofilament light chain [NEFL]), we compared the NULISA
111 results with those obtained, in mostly single-plex formats, on the widely used Quanterix Single
112 molecule array (Simoa) platform. The second aim was to examine the diagnostic accuracies
113 and longitudinal profiles of blood-based NULISAseq targets against neuroimaging measures of
114 A, T and N in a population-based cohort of mostly cognitively normal older adults. Thirdly, we
115 aimed to identify novel plasma I, V, and synaptic markers associated with A β positron emission
116 tomography (PET), tau PET and magnetic resonance imaging (MRI)-based neurodegeneration
117 measures in the same cohort.

118 **Methods**

119 **Participants**

120 The Monongahela Youghiogheny Healthy Aging Team-Neuroimaging (MYHAT-NI) is a sub-
121 cohort of the parent MYHAT study, a population-based prospective study of cognitively normal
122 older adults designed to characterize the prevalence of MCI in older adults with a low
123 socioeconomic status in selected Rust Belt regions in southwestern Pennsylvania [36-38]. The
124 MYHAT study recruited participants aged 65 and older via age-stratified random sampling from
125 publicly available voter registration lists. The MYHAT-NI study recruited a subset of MYHAT
126 participants with a Clinical Dementia Rating (CDR) sum-of-box score [39] of < 1.0 for
127 neuroimaging assessments to investigate the distribution and functional correlates of AD
128 pathologies. For this reason, all MYHAT-NI participants had normal or only very mildly impaired
129 cognition at the time of enrollment which started in 2017. The only exclusion criterion was a
130 contraindication to neuroimaging. The study had two visits: baseline and approximately two-year
131 follow-up. Sociodemographic information was collected at the baseline visit. Blood collection,
132 neurophysiological assessment, and neuroimaging, including [¹¹C] Pittsburgh Compound B
133 (PiB) positron emission tomography (PET) imaging of A β plaques, [¹⁸F]AV-1451 PET imaging of
134 tau pathology, and structural MRI for neurodegeneration, were performed at both baseline and
135 the follow-up visits. Detailed study designs for MYHAT and MYHAT-NI, including subject
136 recruitment strategies, multi-domain cognitive assessments, neuroimaging, and data
137 processing, can be found in previous publications [36, 38]. *APOE* genotyping was determined
138 as previously described [40].

139
140 We classified participants' A, T, and N status according to [¹¹C] PiB PET, [¹⁸F]AV-1451 PET, and
141 MRI scans for cortical thickness, respectively. The A status was based on a global [¹¹C] PiB
142 standardized uptake value ratio (SUVR) computed by volume-weighted averaging of nine
143 composite regional outcomes (anterior cingulate, posterior cingulate, insula, superior frontal

144 cortex, orbitofrontal cortex, lateral temporal cortex, parietal, precuneus, and ventral striatum)
145 [41]. Participants were classified as A+ or A- based on a pre-defined cutoff, with >1.346 as A+
146 [42, 43]. For T status, a composite SUVR was computed for each [¹⁸F]AV-1451 PET by
147 normalizing composite Braak regional values ((Braak I - VI) to FreeSurfer cerebellar gray matter
148 activity [44, 45]. Participants with SUVR > 1.18 were considered T+, <=1.18 as T- [46]. N status
149 was based on an AD-signature composite cortical thickness index derived from a surface-area
150 weighted average of the mean cortical thickness of four FreeSurfer regions of interest (ROIs) –
151 entorhinal, inferior temporal, middle temporal, and fusiform – that are most predictive of AD-
152 specific diagnosis and pathology, with < 2.7 as N+ [42, 47]. The MYHAT-NI study was approved
153 by the University of Pittsburgh Institutional Review Board (STUDY19020264).

154

155 **NULISaseq assay procedures and data processing**

156 Plasma samples were thawed and centrifuged at 10,000xg for 10 min to remove particulates.
157 The supernatants were then analyzed using the NULISaseq CNS disease panel, an innovative
158 proprietary proteomic platform, on an Alamar ARGO™ prototype system, as previously
159 described [34]. In brief, samples were incubated with a cocktail of paired capture and detection
160 antibodies for the included target protein biomarkers and the internal control (IC). The capture
161 antibodies were conjugated with partially double-stranded DNA containing a poly-A tail and a
162 target-specific barcode, while detection antibodies were conjugated with another partially
163 double-stranded DNA containing a biotin group and a matching target-specific barcode. After
164 incubation, the mixtures underwent magnetic bead-based capture, wash, release, recapture,
165 and second round of wash processes to purify the formed immunocomplexes. A ligation mix,
166 including T4 DNA ligase and a specific DNA ligator sequence, was utilized to ligate the proximal
167 ends of DNA attached to the paired antibodies, generating DNA reporter molecules containing
168 unique target and sample-specific barcodes. The reporter DNA levels were then quantified by
169 Next-Generation Sequencing (NGS). The plasma samples were randomized in two plates for

170 the assay. Three assay controls were run side-by-side with samples for each plate, including the
171 sample control (2 replicates/plate), the inter-plate control (3 replicates/plate), and the negative
172 control (2-3 replicates/plate).

173
174 Data normalization was performed to remove potential unwanted technical variation. First, IC-
175 based normalization was done by dividing the target counts for each sample well by that well's
176 IC counts. IPC normalization was achieved by dividing IC-normalized counts by target-specific
177 medians of the IPC (pooled plasma) sample replicates on that plate. Finally, the data was
178 rescaled and log₂-transformed to give a more normal distribution for subsequent statistical
179 analyses. These values are hereafter referred to as NULISA Protein Quantification (NPQ) units.
180 The fold change difference between two groups were calculated as $2^{(\text{difference in NPQ})}$. The plate-
181 specific limit of detection (LOD) was calculated for each target assay by taking the mean plus
182 three times the standard deviation of the unlogged normalized counts for the negative control
183 samples on the plate. LODs were then rescaled and log₂-transformed as above.

184
185 **Procedures for Simoa assays**

186 Simoa assays were performed on an HD-X instrument (Quanterix, Billerica, MA, USA). Prior to
187 the measurements, plasma samples were thawed at room temperature and centrifuged at
188 4000xg for 10 min to remove particulates. Plasma NEFL, GFAP, Aβ₄₂ and Aβ₄₀ were measured
189 with the Neurology 4-Plex E (#103670), p-tau₁₈₁ with the p-tau₁₈₁ V2 Advantage kit (#103714),
190 and p-tau₂₁₇ with the ALZpath Simoa® p-Tau 217 V2 Assay Kit (#104371). Quality control (QC)
191 samples of 2-3 different concentrations for each assay were analyzed at the start and the end of
192 each run to assess the reproducibility of each assay. The average within-run coefficient of
193 variations (CVs) of the QC samples were 3.7% for p-tau₂₁₇, 6.6% for p-tau₁₈₁, 14.3 for NEFL,
194 9.9% for GFAP, 8.9% for Aβ₄₂, and 9.5% for Aβ₄₀. The average between-run CVs were 11.4%

195 for p-tau217, 11.7% for p-tau181, 18.3% for NEFL, 17.8% for GFAP, 13.0% for A β 42, and 14.6%
196 for A β 40.

197

198 **Statistical analysis**

199 All analyses were conducted using MATLAB (version R2021b) or R statistical software version
200 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org/>). In
201 general, we utilized the Wilcoxon rank-sum test for two-group comparisons and the Kruskal-
202 Wallis test for comparisons involving more than two groups. Spearman's rank correlation was
203 used to measure the strength and direction of association between two continuous variables.
204 For demographic characteristics, continuous variables were presented as mean and standard
205 deviation, while categorical variables were reported as counts. Wilcoxon rank-sum tests and
206 Fisher's exact tests were employed to assess the significance of differences between A+ and A-
207 participants for continuous and categorical variables, respectively. Linear mixed models were
208 utilized to assess the association of common AD risk factors, including age, sex, and *APOE* ϵ 4
209 carrier status, with biomarkers.

210

211 The following statistical tests were utilized to explore cross-sectional associations between
212 biomarkers and brain A β and tau pathologies: (1) Wilcoxon rank-sum tests for the univariate
213 significance for the associations between NPQs and dichotomous pathology variables (e.g., A-
214 vs. A+), without adjusting for risk factors; (2) Spearman's rank correlation was used to measure
215 the strength and direction of the associations between NPQs and continuous variables (e.g., A β
216 PET SUVR); (3) linear mixed models (random intercepts) with biomarker NPQs as the
217 dependent variable, visit-specific A β PET status as the independent variables, as well as
218 common risk factors (such as age, sex and *APOE* ϵ 4 carrier status) were used to determine the
219 overall risk factor-adjusted significance combining samples from both visits. False discovery rate
220 corresponding to cutoff p-values were calculated according to the procedure described by Yoav

221 Benjamini and Yosef Hochberg in 1995 [48]. An arbitrary p -value of 0.005 was used as the
222 significance cutoff, which corresponded to 3 to 10% FDR depending on the comparisons.
223 Receiver operating characteristic (ROC) curves and the area under curve (AUC) were
224 calculated using the MATLAB *perfcurve* function, based on scores predicted from generalized
225 linear regression models fitted using the MATLAB *fitglm* function. Confidence intervals were
226 computed using bootstrap with 1000 replicates. DeLong test implemented in the pROC package
227 was used to compare ROC curves [49, 50]. Web app VolcaNoseR was used to create draw the
228 volcano plot [51].

229
230 Longitudinal analysis was limited to participants with plasma samples analyzed at both visits.
231 We calculated the yearly percentage of change for biomarker NPQs and continuous AD
232 pathology variables using this formula: $100 * ([\text{Follow up} - \text{Baseline}]/[\text{Baseline}]) / \Delta \text{Time}$ in
233 years. Wilcoxon rank-sum tests were then used for two-group comparisons, and Spearman's
234 rank correlation was used to measure the association between yearly plasma biomarker
235 changes and the yearly AD pathology change. Due to the relatively short duration between the
236 two visits, we did not expect drastic changes in both blood and neuroimaging biomarker levels.
237 Therefore, we treated the longitudinal analysis as explorative, and the original rather than FDR-
238 adjusted p -values were used to determine significance.

239 **Results**

240 **Cohort characteristics**

241 This study comprised 176 plasma samples from 113 participants (average age 76.7 years at
242 baseline, 54.0% women, and 95.0% non-Hispanic White) from the MYHAT-NI cohort (see Table
243 1 for demographic characteristics). Among them, 63 participants (55.8%) provided plasma
244 samples at two visits (baseline and the 2-year visit). At baseline, 85 (75.2%) participants were
245 classified as A-negative (A-) and 28 (24.8%) as A-positive (A+), while 42 (66.7%) and 21

246 (33.3%) were A- and A+, respectively at the 2-year visit. Regarding tau PET, 74 (65.4%)
247 participants were classified as tau-negative (T-) and 39 (34.5%) as tau-positive (T+) at baseline.
248 At the 2-year visit, 42 (66.7%) participants were T-, and 21 (33.3%) were T+. In terms of
249 neurodegeneration according to cortical thickness, 80 (70.8%) participants were considered N-
250 and 33 (29.2%) N+ at baseline, while at the 2-year visit, there were 42 (66.7%) N- and 20
251 (31.7%) N+ participants. One participant had missing N status at the 2-year visit due to poor
252 MRI quality.

253
254 Most participants were cognitively normal at both visits. Clinical Dementia Rating (CDR)-based
255 cognitive assessment rated 101 participants (89.3%) as cognitively normal (CDR=0) and 10
256 (8.9%) as mildly impaired (CDR=0.5) at baseline. At the 2-year visit, 55 participants (87.2%)
257 were cognitively normal, and 5 (7.9%) were mildly impaired. Two and three participants missed
258 CDR assessments at baseline and the 2-year visit, respectively. Similarly, Mini-Mental State
259 Examination (MMSE) assessment rated 107 (94.6%) participants as cognitively normal (MMSE
260 ≥ 24) and 4 (3.5%) as mildly impaired (MMSE between 19 – 23) at baseline, while all
261 participants at the 2-year visit were cognitively normal.

262

263 **Technical performance and head-to-head comparison of the NULISaseq measurements** 264 **with Simoa assays**

265 A total of 116 target assays were incorporated in the NULISaseq CNS disease panel for this
266 study. The plasma concentration range of these targets spanned a minimum of 6 orders of
267 magnitude according to the concentration estimated by mass spectrometry-based proteomics in
268 the Human Protein Atlas database [52, 53]. Despite the broad dynamic ranges of the protein
269 targets, the vast majority exhibited very high detectability, defined as the percentage of samples
270 above the LOD, with a mean \pm standard deviation (SD) detectability of $97.2\% \pm 13.9\%$ (Fig. 1A).
271 Only three targets – UCHL1, PTN, and pTDP43-409 – had detectability below 70%. The 176

272 plasma samples, including 113 baseline and 63 2-year visit samples, were distributed across
273 two plates for NULISAseq measurements. Each plate included two replicates of a pooled
274 plasma sample to assess assay reproducibility. The median intra-plate and inter-plate CVs were
275 4.34% (interquartile range [IQR]: 2.80%-6.04%) and 3.11% (IQR: 1.41% -5.45%), respectively,
276 suggesting robust assay reproducibility (Fig. 1B and 1C). Only two targets – CNTN2 and NEFH
277 – had inter-plate CVs greater than 20%, a cutoff commonly used for in vitro diagnostic assays.
278 To assess whether the variation depended on protein abundance, we evaluated the association
279 between the intra- or inter-plate CVs and the abundance ranks for targets (n=46) with plasma
280 concentration data available from the Human Protein Atlas database. As depicted in Fig. 1D and
281 1E, both intra- and inter-plate CVs were not influenced by protein abundance, with p -values for
282 Spearman rank correlations being 0.173 and 0.919, respectively.

283
284 We next examined the correlation between NULISAseq measurements and Simoa
285 measurements of selected biomarkers. These included p-tau217, p-tau231, p-tau181, GFAP,
286 NEFL, A β 40, and A β 42. Notably, strong correlations were observed in all pairwise comparisons,
287 with Spearman rank correlation coefficient (ρ) values spanning from 0.318 to 0.880 (Fig. 1F).
288 P-tau217, GFAP, and NEFL demonstrated the strongest between-platform correlation, with ρ
289 of 0.880, 0.873, and 0.847, respectively.

290
291 To compare the diagnostic accuracies of the two measurements in detecting A β PET positivity,
292 we calculated the ROC AUCs using logistic regression models in the baseline samples (Table
293 2). NULISAseq demonstrated comparable performance to Simoa for all seven biomarkers,
294 irrespective of whether common risk factors (age, *APOE* ϵ 4 carrier status, and sex) were
295 included in the models. For example, at baseline, plasma p-tau217 had AUCs of 0.905 (95% CI:
296 0.841-0.969) on NULISA and 0.880 (95% CI: 0.800-0.959) on Simoa. When accounting for risk
297 factors, these AUCs increased to 0.930 (95% CI: 0.878-0.980) and 0.925 (95% CI: 0.874-

298 0.977). The DeLong test showed no significant difference between the AUCs. These findings
299 suggest that despite its highly multiplexed nature, the NULISaseq platform performs
300 equivalently as Simoa for quantifying these biomarkers.

301

302 **Association of NULISaseq targets with PET measure of amyloid pathology (A)**

303 *Cross-sectional association*

304 Several NULISaseq targets showed significant association with the common AD risk factors
305 age, sex, and *APOE* ϵ 4 carrier status (Additional file 1: Figure S1). To account for the potential
306 confounding effect of these risk factors, we utilized linear mixed models, as described in the
307 “Materials and methods” section, to evaluate the adjusted significance for the cross-sectional
308 association between NULISaseq targets and neuroimaging biomarkers.

309

310 A total of 16 targets showed significant association with A β pathology, as determined by A β PET,
311 according to p -value < 0.005, corresponding to approximately 8% FDR (Fig. 2A). Fig. 2B
312 illustrates boxplot distributions of significant targets at baseline and the 2-year visit. NULISaseq
313 plasma p-tau217 demonstrated superior diagnostic accuracy in detecting A β PET positivity. As
314 stated above, plasma p-tau217 achieved AUCs of 0.905 (95% CI: 0.841-0.969) and 0.922 (95%
315 CI: 0.825-0.972) in the baseline and 2-year visit, respectively, when utilized as the sole
316 predictor. Incorporating common AD risk factors – age, sex, and *APOE* ϵ 4 carrier status – raised
317 the AUCs to 0.930 (95% CI: 0.878-0.983) and 0.938 (95% CI: 0.856-0.979), respectively. On
318 average, A+ participants exhibited an 82.8% elevation in plasma p-tau217 levels compared to A-
319 controls. NULISaseq p-tau231 also exhibited significant association. However, the AUCs and
320 fold increases were inferior to plasma p-tau217. The AUCs were 0.718 (95% CI: 0.615-0.822) in
321 the baseline and 0.698 (95% CI: 0.556-0.821) in the 2-year cohorts based on biomarker-only
322 models, which increased to 0.808 (95% CI: 0.717-0.899) and 0.794 (95% CI: 0.652-0.888)

323 respectively, with the inclusion of common risk factors. An overall 30.7% increase was observed
324 comparing p-tau231 levels in A+ participants to those in A- controls. Moreover, GFAP showed
325 high univariate association prior to adjusting for common risk factors, with Wilcoxon rank-sum p -
326 values of 0.0002 for the baseline and 0.006 for the 2-year cohort. However, GFAP showed a
327 strong association with age and APOE ϵ 4 carrier status (Additional file 1: Figure S1B and S1C),
328 and its risk factor-adjusted significance weakened to a p -value of 0.016. The fold increase of
329 GFAP in A+ vs. A- participants was 45.7%. It distinguished A+ from A- participants with AUCs of
330 0.732 (95% CI: 0.640-0.825) and 0.715 (95% CI: 0.569-0.830) in the baseline and 2-year
331 cohorts based on biomarker-only models, and 0.808 (95% CI: 0.717-0.899) and 0.815 (95% CI:
332 0.668-0.926), respectively, after adjusting for common risk factors.

333
334 Contrarily, the other targets that showed significant associations with A β pathology showed
335 decreased protein levels in the A+ versus A- participants (Fig. 2A and 2B). Metalloproteinase
336 inhibitor 3 (TIMP3), a metalloprotease inhibitor involved in regulating proteostasis [54, 55],
337 exhibited the most substantial decrease in protein levels, with a 60%-fold decrease in A+ vs. A-
338 individuals. TIMP3 distinguished A+ and A- participants with AUCs of 0.711 (95%CI: 0.596-
339 0.814) and 0.739 (95%CI: 0.574-0.859) for the baseline and 2-year visit cohorts when used as
340 the sole predictor. The inclusion of common risk factors improved the AUCs to 0.850 (95% CI:
341 0.718-0.923) and 0.882 (95% CI: 0.757-0.946). Malate dehydrogenase subunit 1, MDH1, also
342 emerged as one of the top significant proteins, with the risk factor-adjusted p -value < 0.0001,
343 and decreased at an average of 26% in A+ participants. BDNF, a neurotrophic factor with pivotal
344 roles in regulating synaptic plasticity and neuronal survival, showed an overall 42% reduction in
345 A+ participants.

346
347 Six cytokines—IL7, IL13, CD40LG, CCL13, CCL17, and CCL22—were significantly associated
348 with A β pathology, supporting the involvement of immune response and inflammation in AD.

349 Additional significant targets included SOD1, PGK1, ANXA5, and NULISAseq targets for soluble
350 α -synuclein (SNCA) and oligomeric α -synuclein (OligoSNCA).

351

352 *Longitudinal association*

353 We then investigated the longitudinal relationship between NULISAseq targets and A β
354 pathology. Three cytokines – FGF2, IL4, and IL9 – exhibited A β PET-dependent yearly
355 percentage changes, with Wilcoxon rank-sum test p -values of 0.02, 0.04, and 0.04, respectively
356 (Fig. 3A). The median yearly percentage changes were 9.1%, 1.5%, and 15.4% in A+
357 individuals, compared to -12.8%, -9.5%, and 0.4% in A- participants, respectively, for FGF2, IL4,
358 and IL9. This means that while the cytokine levels increased over time in A+ individuals, large
359 decreases were recorded for A- participants.

360

361 Next, we explored the influence of baseline biomarker levels on the progression of A β
362 pathology, defined as the yearly percentage of change in A β PET SUVR. Apart from p-tau217,
363 five chemokines – CCL26, CCL17, CCL13, CXCL1, and CXCL8 – demonstrated significant
364 associations (Fig. 3B). Higher baseline levels of p-tau217 were associated with more robust
365 increases in A β PET SUVR, with Spearman ρ of 0.367 ($p = 0.003$). On the contrary, elevated
366 baseline levels of all five chemokines were linked with a smaller A β PET SUVR increase, with
367 ρ of -0.363 ($p = 0.004$) for CCL26, -0.343 ($p = 0.006$) for CCL13, -0.331 ($p = 0.008$) for
368 CCL17, -0.300 ($p = 0.017$) for CXCL18, and -0.300 ($p = 0.017$) for CXCL1. Given that a slower
369 increase in A β PET SUVR changes is likely indicative of a more favorable prognostic outcome,
370 these findings suggest that higher levels of these chemokines may confer a protective role in
371 recruiting immune cells to attenuate the accumulation of A β plaques. Consistent with this, all five
372 chemokines were lower in abundance in A+ participants, albeit only CCL13 and CCL17 passed
373 the significance cutoff.

374

375 We further tested the association of plasma biomarker longitudinal changes with A β PET SUVR
376 changes. Seven NULISaseq targets, namely IL5, p-tau217, A β 38, PGF, CCL2, IL4, and
377 VEGFD, showed strong correlations (Additional file 1: Figure S2). The changes of all seven
378 targets were positively correlated with A β PET SUVR changes, suggesting that upward changes
379 of these targets over time might be correlated with more severe A β pathology.

380

381 **Association of NULISaseq targets with tau pathology (T)**

382 *Cross-sectional association*

383 Five NULISaseq targets displayed significant associations with tau PET positivity according to
384 *p*-value cutoff of 0.005, corresponding to FDR of 9%, after adjusting for age, sex and *APOE* ϵ 4
385 carrier status (Fig. 4A). The three top significant targets were p-tau species, namely p-tau231 (*p*
386 = 0.0004), p-tau217 (*p* = 0.0005), and p-tau181 (*p* = 0.003). SFRP1, a Wnt signaling modulator
387 [56], and YWHAG, a member of the 14-3-3 family proteins, were the other significant targets,
388 with *p*-values of 0.003 and 0.004, respectively. All except SFRP1 were increased in T+
389 participants. Average fold increases of 29%, 36%, 20%, and 5% in T+ participants compared
390 with T- controls were observed for p-tau231, p-tau217, p-tau181, and YWHAG, respectively.
391 SFRP1, on the other hand, was decreased at an average of 27%. Among these five targets, p-
392 tau217 had the highest diagnostic accuracy in detecting abnormal tau pathology, with AUCs of
393 0.652 (95% CI: 0.518-0.765) for the baseline cohort and 0.797 (95% CI: 0.660-0.888) for the 2-
394 year cohort. This was followed by p-tau231, which had AUCs of 0.651 (95%CI: 0.522-0.759)
395 and 0.705 (95% CI: 0.560-0.816), respectively. The inclusion of age, sex, and *APOE* ϵ 4 carrier
396 status only slightly improved the AUCs (Additional file 1: Figure S3). Both p-tau217 and p-
397 tau231 showed better diagnostic accuracies in the 2-year cohort, consistent with the expectation
398 that tau pathology worsens over time and that agreement between the plasma and
399 neuroimaging biomarkers improves with disease progression.

400

401 As indicated in Table 1, there was a higher proportion of A+ individuals among those T+. To test
402 whether the A β PET status contributed to the observed association between these significant
403 targets and tau PET status, we evaluated the association by including A β PET status in the
404 linear mixed models. All remained significant except for p-tau217, which was trending towards
405 significance ($p = 0.068$) after adjusting for the effect of A β PET status. The p -values after
406 adjusting for A β PET status were 0.005, 0.003, 0.005, and 0.001 for p-tau231, p-tau181,
407 SFRP1, and YWHAG, respectively.

408

409 *Longitudinal association*

410 A total of 17 targets displayed significant tau pathology-dependent longitudinal changes
411 according to the Wilcoxon rank-sum p -value < 0.05 (Fig. 4B). Chitotriosidase-1 (CHIT1), a
412 known indicator of microglial activation [57, 58], emerged as the top significant target ($p =$
413 0.003). Its levels showed slight increases in T- participants, with a median yearly change of
414 2.7%. T+ participants, on the contrary, exhibited a median yearly decrease of 4.4%. Similarly,
415 CHI3L1 (YKL-40), a biomarker for reactive astrogliosis, also exhibited an increase (median
416 yearly change of 16.3%) in T- participants but a decrease in T+ individuals (median yearly
417 change of -2.8%). These observations suggest that A β pathology may trigger early activation of
418 the brain's immune system to mitigate damage, but this response may plateau or decrease as
419 more downstream pathology, such as tau pathology, becomes apparent. Alternatively, lower glial
420 activation in response to amyloid and tau pathology may reflect the resilience of pathologically
421 burdened but cognitively preserved individuals [59, 60].

422

423 PGF, PDGFRB, and VEGFA, important players in maintaining cerebrovascular integrity, also
424 showed tau pathology-dependent longitudinal changes. All three exhibited a declining trend over
425 time in T+ participants (median yearly change: PGF, -4.1%; PDGFRB, -1.5%; VEGFA, -5.7%),

426 contrasting with either stable or increased levels observed in T- individuals (median yearly
427 change: PGF, -0.6%; PDGFRB, 5.8%; VEFGA, -0.6%). These findings suggest that tau
428 pathology may be linked to the deterioration of vascular structure. NPTX1, a biomarker of
429 excitatory synaptic pathology, similarly displayed a decreasing trend in T+ participants (median -
430 4.1%/year), in contrast to a slight upward change in T- controls (median 1.6%/year). Additional
431 targets with tau pathology-dependent longitudinal changes included 4 cytokines (CCL2, CSF2,
432 IL17A, and CX3CL1), proteins involved in synaptic and neuronal dysfunction (VSNL1, CNTN2,
433 and FABP3), IGF1, SLIT2, NEFH, and SQSTM1.

434
435 Baseline levels of three NULISaseq targets, IL12p70, IFNG, and RUVBL2, were significantly
436 associated with tau PET changes between the two visits (Additional file 1: Figure S4A). High
437 baseline levels of IL12p70 and IFNG, two presumptive pro-inflammatory cytokines, were
438 associated with faster progression of tau pathology, as determined by a more pronounced
439 increase in tau PET composite, with ρ of 0.288 ($p = 0.022$) and 0.269 ($p = 0.033$), respectively.
440 The opposite relationship was recorded for RUVBL2, an AAA-type ATPase involved in
441 regulating pro-inflammatory response. A higher baseline level of RUVBL2 was associated with a
442 smaller increase in tau pathology, with a ρ of -0.253 ($p = 0.046$).

443
444 The longitudinal change of seven NULISaseq targets correlated significantly with tau PET
445 SUVR change (Additional file 1: Figure S4B). Interestingly, the list included three tau targets, all
446 of which showed positive associations, namely MAPT (t-tau; $\rho = 0.348$; $p = 0.005$), p-tau217
447 ($\rho = 0.293$; $p = 0.020$) and p-tau181 ($\rho = 0.251$; $p = 0.047$). Other targets on the list included
448 SOD1 ($\rho = 0.359$; $p = 0.004$), IL6R ($\rho = 0.292$; $p = 0.020$), CSF2 ($\rho = 0.280$; $p = 0.027$),
449 and CD40LG ($\rho = -0.262$; $p = 0.038$).

450

451 **Association of NULISaseq targets with neurodegeneration (N)**

452 *Cross-sectional association*

453 Twenty NULISaseq targets exhibited significant associations with N status when assessed
454 using univariate analysis with dichotomous outcomes (N- vs. N+) or Spearman correlations with
455 MRI-determined cortical thickness (p -value < 0.005 , corresponding to $\sim 5\%$ FDR) without
456 adjusting for the effects of common risk factors. The list of significant targets included NEFL, a
457 classical biomarker for neurodegeneration, 8 cytokines (IL2, IL6, IL10, IL16, TNF, CCL3,
458 CXCL10, and TFAFA5), proteins previously linked to synaptic and neuronal network defects
459 (CALB2, FABP3, and REST), proteins involved in regulating proteostasis (PSEN1, and
460 SQSTM1), proteins involved in acute-phase response (CRP, SAA1 and SAA2), and ICAM1 and
461 VEGFA, both critical for maintaining cerebrovascular integrity. As depicted in the heatmap in Fig.
462 5A, these targets exhibited a consistent trend in both the baseline and 2-year visit samples, with
463 all targets upregulated in N+ individuals compared to N- controls. The repressor element-1
464 silencing transcription factor (REST), a zinc finger transcription factor with potential
465 neuroprotective function [61], was one of the top significant targets, with p -values of 0.004 and
466 0.0008 and AUCs of 0.671 (95% CI 0.561-0.769) and 0.766 (95% CI 0.600-0.883) for the
467 baseline and 2-year visit, respectively (Fig. 5B). NEFL showed a strong association in the
468 baseline samples ($p = 0.003$) but not in the 2-year visit samples ($p = 0.126$) (Fig. 5B).

469
470 However, after adjusting for age, sex, and *APOE* $\epsilon 4$ carrier status, the associations weakened
471 for most of these targets, with SQSTM1 being the only target retaining a p -value < 0.005 .
472 SQSTM1 exhibited strong association with N status in both baseline and 2-year cohorts, with
473 Wilcoxon rank-sum p -values of 0.0001 and 0.006, respectively (Fig. 5B). It distinguished N+
474 from N- participants with accuracies of 0.729 (95% CI 0.606-0.829) at baseline and 0.713 (95%
475 CI 0.548 -0.854) at the 2-year visit (Fig. 5B). The inclusion of common risk factors (age, sex,

476 and *APOE* ϵ 4 carrier status) improved the accuracies to 0.776 (95% CI 0.674-0.860) and 0.848
477 (95% CI 0.703 -0.933).

478

479 *Longitudinal association*

480 MME and IL10 demonstrated neurodegeneration-dependent abundance changes, with
481 increases in N+ participants (median change/year: MME, 1.7%; IL10, 9.4%) and decreases in
482 N- individuals (median change/year: MME, 19.2%; IL10, 3.8%) (Fig. 5C).

483

484 Baseline levels of five NULISaseq targets – KLK6, CCL11, ARGN, TNF, and PGK1 – were
485 significantly associated with cortical thickness change, all showing positive correlations,
486 suggesting higher levels of these targets may be linked with a slower rate of neurodegeneration
487 (Additional file 1: Figure S5A). The longitudinal change of five targets – PTN, YWHAZ, GOT1,
488 NRGN, A β 42, and SNCA (oligomer) – was significantly correlated with cortical thickness change
489 (Additional file 1: Figure S5B). Among them, A β 42 exhibited a positive correlation with cortical
490 thickness change, with *rho* of 0.264 ($p = 0.037$), suggesting that a decrease in A β 42 levels is
491 associated with more severe neurodegeneration, i.e., a decrease in cortical thickness.
492 Conversely, changes in the other four targets were negatively associated with cortical thickness
493 change, with *rho* of -0.335 ($p = 0.008$), -0.291 ($p = 0.021$), -0.290 ($p = 0.022$), -0.284 ($p =$
494 0.025), for PTN, YWHAZ, GOT1, and NRGN, respectively.

495

496 **Discussion**

497 In this study, we have demonstrated the feasibility of concurrent immunoassay-based analysis
498 of 116 protein markers in blood to provide diagnostic and prognostic information in preclinical
499 AD. Our results identified several novel inflammation, synaptic, and vascular markers in blood
500 significantly associated with brain A β , tau, and neurodegeneration burden at baseline and at the

501 two-year follow-up. These were not limited to markers such as p-tau217, p-tau231, p-tau181,
502 and GFAP, the elevation of which have consistently shown strong associations with brain A β
503 and/or tau load but included novel protein targets that inform about the disease state of the
504 individual in different pathological stages across the biological AD continuum. Importantly, this is
505 the first time several of these protein targets have shown validated technical and clinical
506 biomarker potential in blood. These included the cerebrovascular markers ICAM1, VCAM1,
507 PDGFRB, PGF, VEGFA, and VEGFD, the synaptic marker NPTX1, and the glial markers CHIT1
508 and CHI3L1 (YKL-40).

509
510 Concurrent measurement of a large number of protein analytes presents technical challenges
511 that most available immunoassay platforms struggle to address. Problems such as reagent
512 cross-activity and the dynamic range of target analyte abundance impede the multiplexing
513 capacity of immunoassays. Technological breakthroughs, including antibody arrays, proximity
514 ligation assay (PLA), proximity extension assay, microsphere bead capture technology by
515 Luminex, and slow off-rate modified aptamer assay (SOMAscan), have enabled the
516 simultaneous measurement of hundreds to thousands of plasma proteins [62]. However, these
517 technologies often use single antibodies that only provide partial information about the protein
518 targets, neglecting ubiquitous post-translational modifications that they undergo *in vivo*. The
519 NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) technology, which is built as an
520 advancement of the PLA technique, integrates multiple mechanisms to enhance the
521 performance of PLA, including a proprietary sequential immunocomplex capture and release
522 mechanism for background reduction, next-generation sequencing-based signal readout, and
523 fine-tuning the ratio of unconjugated "cold" antibodies to DNA-conjugated "hot" antibodies to
524 mitigate sequencing reads of high-abundant proteins. This provides the proteomic platform the
525 capability to detect hundreds of protein biomarkers with attomolar sensitivity and ultrabroad

526 dynamic range [34]. The high detectability rate and low detection limits for the various protein
527 targets in this study support this.

528
529 The strong correlation and comparable diagnostic accuracies in the head-to-head comparisons
530 with Simoa assays indicate that both techniques measure equivalent pools of the protein targets
531 available in the blood. It is worth mentioning that the exceptional correlation with the Simoa
532 ALZPath assay could be due to the two assays using the same p-tau217 monoclonal antibody.

533
534 The high performance of plasma p-tau217, p-tau231, and GFAP to identify abnormal A β PET
535 scans in this mostly cognitively normal cohort is corroborated by findings from several recent
536 studies based on results from other analytical platforms [9, 63-67]. Importantly, we identified
537 biomarkers with decreased levels in A+ participants, akin to plasma A β 42 and A β 42/40,
538 indicating reduced availability in blood with progressive bran A β pathology. The decreases in
539 TIMP3 are consistent with previously reported lower TIMP3 levels in AD patients [68]. TIMP3
540 also promotes brain A β production via inhibiting α -secretase cleavage of the amyloid precursor
541 protein [69]. Reduction in MDH1 levels supports previous reports on the involvement of altered
542 energy metabolism in late-onset AD [70, 71] while BDNF has been implicated in a protective
543 role against A-induced neurotoxicity [72]. Several studies have also linked multiple inflammatory
544 cytokines to A β pathology in AD cases and those resilient to AD [59, 73, 74]. FGF2 gene
545 transfer reversed hippocampal function and cognitive decline in mouse models [75]. Similarly,
546 beneficial effects of IL4 have been reported in animal models [75].

547
548 Plasma p-tau217, p-tau231, and p-tau181 were the leading markers to identify abnormal tau-
549 PET scans. However, accounting for A β PET status in the combined A and T positivity analysis
550 suggested that the results were partly explained by the strong association of these markers with
551 A β pathology. This could mean that the tau forms containing these phosphorylation sites

552 become available in blood in the early phases of A β plaque pathology. Aside from blood-based
553 tau markers, YWHAG [76-78] and SFRP1 [79] showed strong associations with AD. The
554 reduction in SFRP1 levels might be explained by its direct binding to A β plaques [80].
555 Importantly, the existing evidence from these markers has been built in CSF and brain tissue
556 samples. Here, we extend these findings to blood.

557
558 The reactive astrogliosis marker CHI3L1 (YKL-40) and the microglia activation marker CHIT1
559 have repeatedly been shown to be associated with tau pathology; however, the evidence base
560 has only been built using CSF samples [6, 81, 82]. The same applies to the vascular markers
561 PGF, PDGFRB, and VEGFA, and the synaptic marker NPTX1, the biomarker potential of which
562 have been demonstrated in CSF [21, 83-89]. Translation of these prior findings to plasma
563 indicates that the molecular processes in AD involving these markers are reflected in the blood
564 stream, expanding the repertoire of blood-based indicators of brain pathophysiological changes.

565
566 Our study identified several plasma biomarkers with a strong association with
567 neurodegeneration assessed based on MRI-determined cortical thickness, including NEFL,
568 which is a proven general marker of neuronal injury [90, 91]. Not surprisingly, several cytokines,
569 including IL2, IL6, IL10, IL16, TNF, CCL3, CXCL10, and TFAFA5, also showed significant
570 association with neurodegeneration, reinforcing the close relationship between
571 neuroinflammation and neurodegenerative processes [92, 93].

572
573 Two vascular proteins, ICAM1 and VEGFA, were on the significant list, consistent with the
574 expected involvement of neurovascular dysfunction in neuroinflammation and
575 neurodegeneration [94]. ICAM1 is a transmembrane glycoprotein expressed in multiple cell
576 types and plays a key role in maintaining the blood brain barrier (BBB) [95]. Its expression is
577 induced by neuroinflammation, leading to increased leukocyte transmigration across the BBB, a

578 pivotal event in the pathogenesis of various brain diseases, including AD [96-98]. Consistent
579 with this, our study observed elevated ICAM1 levels in participants with neurodegeneration,
580 aligning with previous research [18, 20]. VEGFs have complex associations with neurological
581 diseases, exhibiting neuroprotective and neuro-destructive potential [24, 25, 99]. We observed
582 elevated VEGFA levels in N+ participants and a faster decline in VEGFA levels in T+
583 participants, suggesting a potential staging effect. Interestingly, a recent study showed that a
584 low level of VEGFA, measured with assays from Meso Scale Discovery, was associated with
585 accelerated neocortical tau accumulation in preclinical A+ participants in the Harvard Aging
586 Brain Study [100].

587
588 Synaptic and neuronal network dysfunction, along with aberrant proteostasis, represent two of
589 the eight pathological hallmarks of neurodegenerative diseases [35]. In alignment with this, our
590 study found significant associations between neurodegeneration, three synaptic/network
591 proteins (CALB2, FABP3, and REST), and two proteostatic regulators (PSEN1 and SQSTM1).
592 Notably, among all targets with significant association with neurodegeneration, only SQSTM1
593 withstood corrections for age, sex, and *APOE* ϵ 4 genotype, revealing it as a potentially novel
594 neurodegeneration biomarker for AD. SQSTM1, a scaffold protein with a critical role in
595 macroautophagy, has been previously linked to several neurodegenerative diseases, including
596 AD [101-103].

597
598 IL10 and MME were the top hits with differential longitudinal change in N+ vs. N- participants.
599 Several studies support their roles as markers of neurodegeneration status. For example, an
600 animal model study suggested that the mechanisms of action of IL-10 as an inflammatory
601 response might be through the activation of microglia, which leads to IL-6 activation and
602 abnormal phosphorylation of tau [104]. MME, also known as neprilysin, is an integral
603 membrane-bound metalloproteinase (MMP) and one of the key enzymes involved in A β

604 degradation [105]. MMPs have been found to exhibit dual roles in AD pathogenesis. On the one
605 hand, they can reduce the amount of A β deposits by degrading A β peptides [106, 107]. On the
606 other hand, their levels can be induced by A β , potentially leading to brain parenchymal
607 destruction [108, 109]. Interestingly, in addition to demonstrating significant longitudinal changes
608 between N+ and N- participants, MME exhibited lower levels in A+ participants compared to A-
609 controls, yet higher levels in N+ participants compared to N-, supporting its potential utility as a
610 staging biomarker for AD.

611
612 Interestingly, while a number of cytokines (IL2, IL6, IL10, IL16, TNF, CCL3, CXCL10, and
613 TFAFA5) were increased in participants with neurodegeneration, several cytokines (IL7, IL13,
614 CD40LG, CCL13, CCL17, and CCL22) were found to be decreased in participants with A β
615 pathology. Additionally, higher baseline levels of several chemokines (CCL26, CCL17, CCL13,
616 CXCL1, and CXCL8) were significantly associated with slower progression of A β pathology.
617 Given that most participants with A β pathology were cognitively normal, and neurodegeneration
618 is presumed to occur at a later stage than the early phase of A β pathology, our results support
619 the biphasic roles of neuroinflammation, with protective effects in the early stages and
620 potentially detrimental effects in the later stages. These findings are in line with the recognized
621 multifaceted impact of neuroinflammation on AD pathogenesis [110, 111].

622
623 Strengths of this study include (i) technical validation of the new NULISA platform; (ii) direct
624 comparison of the clinical performances of biomarkers measured using NULISA assays vs. with
625 Simoa assays; (iii) focus on a population-based cohort to provide information closer to the real
626 world than most clinical research-based cohorts; (iv) emphasis on predominantly cognitively
627 normal participants with emerging pathological phenotypes, to test the sensitivity of the NULISA
628 platform to these incipient changes; (v) availability of paired neuroimaging measures of A β , tau,
629 and neurodegeneration, making it possible to identify inflammatory, vascular and synaptic

630 markers associated with abnormal changes in different biologically defined disease stages; and
631 (vi) repeated neuroimaging evaluations and blood collection over a two-year interval, allowing to
632 examine biomarker changes within that timeframe. Limitations include the lack of validation in
633 diverse cohorts.

634 **Conclusions**

635 Together, this targeted proteomic study has established that results from the NULISA platform
636 are equivalent to those from Simoa HDX. Additionally, the strong multiplexing capabilities of
637 NULISA allowed for the evaluation of dozens of verified and putative protein biomarkers in a
638 longitudinal preclinical AD cohort. We identified several neuroinflammation, synaptic, and
639 vascular markers that have been previously linked to AD, but their measurement in plasma was
640 hitherto not established. Our findings, therefore, pave the way for independent validation of
641 these plasma markers to enable their widespread use for diagnostic, prognostic, and
642 monitoring.

643 **Abbreviations**

644	A β	Amyloid-beta
645	AD	Alzheimer's disease
646	AUC	Area under Curve
647	BBB	Blood brain barrier
648	CDR	Clinical dementia rating
649	CNS	Central nervous system
650	CSF	Cerebrospinal fluid
651	CV	Coefficient of variation
652	FDR	False discovery rate
653	IC	Internal control
654	IQR	Interquartile range

655	LOD	Limit of detection
656	MCI	Mild cognitive impairment
657	MMSE	Mini-Mental State Examination
658	MRI	Magnetic resonance imaging
659	MYHAT	Monongahela Youghiogheny Healthy Aging Team
660	MYHAT NI	Monongahela Youghiogheny Healthy Aging Team-Neuroimaging
661	NPQ	NULISA protein quantification
662	NULISA	NUcleic acid-linked Immuno-Sandwich Assay
663	NULISAseq	NULISA with next-generation sequencing readout
664	PiB	Pittsburgh compound-B
665	PLA	Proximity ligation assay
666	p-tau	Phosphorylated tau
667	PET	Positron emission tomography
668	QC	Quality control
669	ROC	Receiver operating characteristic
670	ROIs	Regions of interest
671	SD	Standard deviation
672	Simoa	Single-molecule array
673	SUVR	Standardized uptake value ratio

674

675 **Acknowledgments**

676 We thank all members of the Karikari Laboratory and Dr. Rebecca Deek for statistical advice.

677 We are indebted to the participants, family members, and staff of the MYHAT-NI study.

678 **Author contributions**

679 TKK, MIK, ADC, BES, and MG contributed to the study's conception and design. BES and MG
680 ran MYHAT and MYHAT-NI cohorts. ADC, VLV, TAP, PCLF, BB, GP, OIL and WEK contributed to
681 neuroimaging data collection and analysis. TKL, AS, PCF, BB, and PG performed biochemical
682 assays. MIK performed genotyping experiments. XZ and YC performed data analysis and
683 produced the figures. XZ and TKK were major contributors in writing the manuscript. All authors
684 contributed to and approved the final version of the manuscript.

685

686 **Funding**

687 TKK was supported by the NIH (R01 AG083874, U24 AG082930, P30 AG066468, RF1
688 AG052525-01A1, R01 AG053952-05, R37 AG023651-17, RF1 AG025516-12A1, R01
689 AG073267-02, R01 AG075336-01, R01 AG072641-02, P01 AG025204-16) and the Alzheimer's
690 Association (#AARF-21-850325). MDI was supported by NIH/NIA grants P01AG14449 and
691 P01AG025204. The MYHAT study was supported by R37 AG023651-17 and MYHAT-NI by R01
692 AG052521.

693 **Data availability**

694 De-identified, cohort-level data will be shared at the request of verified investigators to replicate
695 procedures and results reported in this article. Data transfer agreements in accordance with US
696 legislation and the decisions of the University of Pittsburgh's Institutional Review Board, which
697 covers the jurisdiction of the MYHAT-NI study, may need to be established.

698 **Declarations**

699 **Ethics approval and consent to participate**

700 All plasma samples were obtained with full written informed consent and approved by the
701 University of Pittsburgh Institutional Review Board (STUDY19020264).

702 **Consent for publication**

703 Not applicable.

704 **Competing interest**

705 The authors declare that they have no competing interests

706 **Supplementary Information**

- 707 • Additional file 1: Supplementary Figure S1 to S5

708

709 **Tables**

- 710 • **Table 1:** Participant characteristics in the MYHAT-NI cohort
- 711 • **Table 2:** Diagnostic accuracy (ROC analysis) of NULISaseq and Simoa biomarkers for
712 A β PET positivity.

713

714 **Figure legends**

715 **Fig. 1:** Performance of the NULISaseq CNS disease panel. **A** Box plots illustrating the
716 detectability of 116 targets in 176 plasma samples collected from 113 MYHAT-NI participants.
717 The y-axis represents NPQ - LOD, where values >0 indicate detectability. On each box, the
718 central mark indicates the median, and the bottom and top edges of the box indicate the 25th
719 and 75th percentiles, respectively. The whiskers extend to the most extreme data points not
720 considered outliers, and the outliers are plotted individually using the '+' marker symbol. Data
721 points were considered outliers if they were greater than $q3 + 1.5 \times (q3 - q1)$ or less than $q1 -$
722 $1.5 \times (q3 - q1)$, where $q1$ and $q3$ are the 25th and 75th percentiles of the sample data. **B-C**

723 Histogram distribution of intra-plate (**B**) and inter-plate (**C**) coefficient of variations (CVs). **D-E**
724 Scatterplot distributions between abundance rank and intra-plate (**D**) or inter-plate (**E**) CVs.
725 Intra- and inter-plate CVs were calculated based on results of a pooled plasma sample (SC),
726 measured in duplicate each in two different plates. Abundance rank was based on the mass
727 spectrometry-estimated protein abundance in the Human Protein Atlas (downloaded on
728 12/24/2023). (**F**) Scatterplot distributions illustrating the correlation of protein levels measured
729 using NULISAseq and Simoa method. *Rho* and *p* values were determined using Spearman
730 rank-based correlation. Purple lines indicated the least square regression lines. NPQ, NULISA
731 Protein Quantification; LOD, limit of detection.

732 **Fig. 2:** Cross-sectional association of NULISAseq targets with amyloid pathology (A). **A** Volcano
733 plot of $-\log_{10}(\text{p-value})$ versus $\log_2(\text{fold change})$ comparing biomarker abundances (NPQ) in
734 samples from A+ participants (n=49) vs. A- controls (n=127). Significant targets are shown in
735 red (higher in A+) or blue (lower in A+) circles. Grey circles represent non-significant targets. **B**
736 Boxplot distributions of significant NULISAseq targets, separated by A status and visit. P-values
737 on top of the boxplots were for the whole data combining both visits and were determined using
738 linear mixed models (random intercepts) with NPQs as the dependent variable, visit-specific A
739 status as the independent variables, adjusting for covariates age, sex, and APOE $\epsilon 4$ carrier
740 status. Significance determination was based on $p\text{-value} < 0.005$, corresponding to $\sim 8\%$ FDR.

741 **Fig. 3:** Longitudinal association between NULISAseq targets and amyloid pathology (A). **A**
742 Boxplots illustrating the distribution of yearly biomarker abundance change by A status. P-values
743 were based on two-sided Wilcoxon rank sum tests. **B** Scatterplots for the correlation between
744 yearly longitudinal A β PET SUVR change and baseline biomarker levels. The strength of the
745 correlation was assessed based on Spearman's ranks. Purple lines indicated the least square
746 regression lines.

747 **Fig. 4:** Association of NULISaseq targets with tau pathology (T). **A** Boxplots of NULISaseq
748 targets with significant cross-sectional associations with T status, separated by T status and
749 visit. P-values on top of the boxplots were for the whole data combining both visits and were
750 determined using linear mixed models (random intercepts) with NPQs as the dependent
751 variable, visit-specific T status as the independent variables, adjusting for covariates age, sex
752 and APOE ϵ 4 carrier status. Significance determination was based on p-value < 0.005,
753 corresponding to ~9% FDR. **B** Boxplots illustrating the distribution of yearly biomarker
754 abundance change by T status. P-values were based on two-sided Wilcoxon rank sum tests.

755 **Fig. 5:** Association of NULISaseq targets with neurodegeneration (N). **A** Heatmaps illustrating
756 the abundance levels of NULISaseq with significant univariate association with N status
757 (unadjusted for covariates). The NPQ values were standardized for each protein target using z-
758 scores. **B** Boxplots of selected NULISaseq targets, separated by N status and visit. P-values on
759 top of the boxplots were for the whole data combining both visits and were determined using
760 linear mixed models (random intercepts) with NPQs as the dependent variable, visit-specific N
761 status as the independent variables, adjusting for covariates age, sex, and APOE ϵ 4 carrier
762 status. **C** Boxplots illustrating the distribution of yearly biomarker abundance change by N
763 status. P-values were based on two-sided Wilcoxon rank sum tests.

764

765 **References**

- 766 1. **Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's**
767 **Association Workgroup** [<https://aaic.alz.org/diagnostic-criteria.asp>]
768 2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM,
769 Jagust W, Jessen F, Karlawish J, et al: **NIA-AA Research Framework: Toward a**

- 770 **biological definition of Alzheimer's disease.** *Alzheimer's & Dementia* 2018, **14**:535-
771 562.
- 772 3. Selkoe DJ: **Alzheimer's disease is a synaptic failure.** *Science* 2002, **298**:789-791.
- 773 4. Masliah E: **Mechanisms of synaptic dysfunction in Alzheimer's disease.** *Histol*
774 *Histopathol* 1995, **10**:509-519.
- 775 5. Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M,
776 Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, et al: **Changes in Synaptic**
777 **Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease**
778 **Cerebrospinal Fluid.** *Mol Cell Proteomics* 2019, **18**:546-560.
- 779 6. Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang Y-T, Leffa DT, Brum WS,
780 Benedet AL, Ashton NJ, De Bastiani MA, et al: **Astrocyte biomarker signatures of**
781 **amyloid- β and tau pathologies in Alzheimer's disease.** *Molecular Psychiatry* 2022,
782 **27**:4781-4789.
- 783 7. Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria
784 K, Molinuevo JL, Grau-Rivera O, González Escalante A, Kollmorgen G, et al: **Astrocyte**
785 **biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.**
786 *Alzheimer's & Dementia* 2024, **20**:483-493.
- 787 8. Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R,
788 Molinuevo JL: **Cerebrospinal fluid level of YKL-40 protein in preclinical and**
789 **prodromal Alzheimer's disease.** *J Alzheimers Dis* 2014, **42**:901-908.
- 790 9. Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE,
791 Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O: **Plasma GFAP is an early**
792 **marker of amyloid- β but not tau pathology in Alzheimer's disease.** *Brain* 2021,
793 **144**:3505-3516.
- 794 10. Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque
795 Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al: **Early**

- 796 **increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-**
797 **neurodegeneration but not with amyloid- β pathology.** *Molecular Neurodegeneration*
798 2019, **14**:1.
- 799 11. Park S-H, Lee E-H, Kim H-J, Jo S, Lee S, Seo SW, Park H-H, Koh S-H, Lee J-H: **The**
800 **relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's**
801 **disease.** *Scientific Reports* 2021, **11**:13050.
- 802 12. Rauchmann B-S, Schneider-Axmann T, Alexopoulos P, Perneczky R: **CSF soluble**
803 **TREM2 as a measure of immune response along the Alzheimer's disease**
804 **continuum.** *Neurobiology of Aging* 2019, **74**:182-190.
- 805 13. Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P,
806 Öhrfelt A, Blennow K, Hardy J, Schott J, et al: **Increased cerebrospinal fluid soluble**
807 **TREM2 concentration in Alzheimer's disease.** *Molecular Neurodegeneration* 2016,
808 **11**:3.
- 809 14. Hok AHYS, Del Campo M, Boiten WA, Stoops E, Vanhooren M, Lemstra AW, van der
810 Flier WM, Teunissen CE: **Neuroinflammatory CSF biomarkers MIF, sTREM1, and**
811 **sTREM2 show dynamic expression profiles in Alzheimer's disease.** *J*
812 *Neuroinflammation* 2023, **20**:107.
- 813 15. Motta C, Finardi A, Toniolo S, Di Lorenzo F, Scaricamazza E, Loizzo S, Mercuri NB,
814 Furlan R, Koch G, Martorana A: **Protective Role of Cerebrospinal Fluid Inflammatory**
815 **Cytokines in Patients with Amnesic Mild Cognitive Impairment and Early**
816 **Alzheimer's Disease Carrying Apolipoprotein E4 Genotype.** *Journal of Alzheimer's*
817 *Disease* 2020, **76**:681-689.
- 818 16. Doroszkiewicz J, Kulczynska-Przybik A, Dulewicz M, Borawska R, Krawiec A, Slowik A,
819 Mroczko B: **The cerebrospinal fluid interleukin 8 (IL-8) concentration in Alzheimer's**
820 **disease (AD).** *Alzheimer's & Dementia* 2021, **17**:e051317.

- 821 17. Taipa R, das Neves SP, Sousa AL, Fernandes J, Pinto C, Correia AP, Santos E, Pinto
822 PS, Carneiro P, Costa P, et al: **Proinflammatory and anti-inflammatory cytokines in**
823 **the CSF of patients with Alzheimer's disease and their correlation with cognitive**
824 **decline.** *Neurobiology of Aging* 2019, **76**:125-132.
- 825 18. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K,
826 Hansson O: **CSF biomarkers of neuroinflammation and cerebrovascular**
827 **dysfunction in early Alzheimer disease.** *Neurology* 2018, **91**:e867-e877.
- 828 19. Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg
829 H, Blennow K, Carlsson CM, Neuhaus J, et al: **Cerebrospinal Fluid and Plasma**
830 **Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's**
831 **Disease Pathology and Neuronal Damage.** *Journal of Alzheimer's Disease* 2018,
832 **62**:385-397.
- 833 20. Rauchmann B-S, Sadlon A, Perneczky R, for the Alzheimer's Disease Neuroimaging I:
834 **Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal**
835 **Fluid.** *Journal of Alzheimer's Disease* 2020, **73**:1615-1626.
- 836 21. Miners JS, Kehoe PG, Love S, Zetterberg H, Blennow K: **CSF evidence of pericyte**
837 **damage in Alzheimer's disease is associated with markers of blood-brain barrier**
838 **dysfunction and disease pathology.** *Alzheimer's Research & Therapy* 2019, **11**:81.
- 839 22. Wang J, Fan D-Y, Li H-Y, He C-Y, Shen Y-Y, Zeng G-H, Chen D-W, Yi X, Ma Y-H, Yu J-T,
840 Wang Y-J: **Dynamic changes of CSF sPDGFR β during ageing and AD progression**
841 **and associations with CSF ATN biomarkers.** *Molecular Neurodegeneration* 2022,
842 **17**:9.
- 843 23. Lv X, Zhang M, Cheng Z, Wang Q, Wang P, Xie Q, Ni M, Shen Y, Tang Q, Gao F, China
844 Aging Neurodegenerative Disorder Initiative C: **Changes in CSF sPDGFR β level and**
845 **their association with blood-brain barrier breakdown in Alzheimer's disease with**

- 846 **or without small cerebrovascular lesions. *Alzheimer's Research & Therapy* 2023,**
847 **15:51.**
- 848 24. Storkebaum E, Carmeliet P: **VEGF: a critical player in neurodegeneration. *J Clin***
849 ***Invest* 2004, 113:14-18.**
- 850 25. Garcia KO, Ornellas FL, Martin PK, Patti CL, Mello LE, Frussa-Filho R, Han SW, Longo
851 **BM: Therapeutic effects of the transplantation of VEGF overexpressing bone**
852 **marrow mesenchymal stem cells in the hippocampus of murine model of**
853 **Alzheimer's disease. *Front Aging Neurosci* 2014, 6:30.**
- 854 26. Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D,
855 Vanderstichele H, Vanmechelen E, et al: **Synaptic biomarkers in CSF aid in**
856 **diagnosis, correlate with cognition and predict progression in MCI and**
857 **Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical***
858 ***Interventions* 2019, 5:871-882.**
- 859 27. Dulewicz M, Kulczyńska-Przybik A, Słowik A, Borawska R, Mroczko B: **Neurogranin**
860 **and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in**
861 **Alzheimer's Disease. *Journal of Clinical Medicine* 2021, 10:4575.**
- 862 28. Libiger O, Shaw LM, Watson MH, Nairn AC, Umaña KL, Biarnes MC, Canet-Avilés RM,
863 Jack Jr. CR, Breton Y-A, Cortes L, et al: **Longitudinal CSF proteomics identifies**
864 **NPTX2 as a prognostic biomarker of Alzheimer's disease. *Alzheimer's & Dementia***
865 **2021, 17:1976-1987.**
- 866 29. Pilotto A, Bongianini M, Tirloni C, Galli A, Padovani A, Zanusso G: **CSF alpha-synuclein**
867 **aggregates by seed amplification and clinical presentation of AD. *Alzheimer's &***
868 ***Dementia* 2023, 19:3754-3759.**
- 869 30. Anderson NL, Anderson NG: **The Human Plasma Proteome: History, Character, and**
870 **Diagnostic Prospects*. *Molecular & Cellular Proteomics* 2002, 1:845-867.**

- 871 31. Galasko D, Golde TE: **Biomarkers for Alzheimer's disease in plasma, serum and**
872 **blood - conceptual and practical problems.** *Alzheimer's Research & Therapy* 2013,
873 **5:10.**
- 874 32. Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Leleental N,
875 Kornhuber J, Hansson O, Minthon L, Spitzer P, et al: **Characterization of the**
876 **postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma**
877 **samples from Alzheimer's disease patients and healthy controls.** *Alzheimers Res*
878 *Ther* 2015, **7:40.**
- 879 33. De Vos A, Jacobs D, Struyfs H, Franssen E, Andersson K, Portelius E, Andreasson U, De
880 Surgeloose D, Hernalsteen D, Slegers K, et al: **C-terminal neurogranin is increased**
881 **in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.** *Alzheimer's*
882 *& Dementia* 2015, **11:1461-1469.**
- 883 34. Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, Cha K, Moua M, Qiu X,
884 Xu X, et al: **NULISA: a proteomic liquid biopsy platform with attomolar sensitivity**
885 **and high multiplexing.** *Nature Communications* 2023, **14:7238.**
- 886 35. Wilson DM, 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM,
887 Dewachter I: **Hallmarks of neurodegenerative diseases.** *Cell* 2023, **186:693-714.**
- 888 36. Sullivan KJ, Liu A, Chang CH, Cohen AD, Lopresti BJ, Minhas DS, Laymon CM, Klunk
889 WE, Aizenstein H, Nadkarni NK, et al: **Alzheimer's disease pathology in a**
890 **community-based sample of older adults without dementia: The MYHAT**
891 **neuroimaging study.** *Brain Imaging Behav* 2021, **15:1355-1363.**
- 892 37. Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC: **Mild cognitive impairment:**
893 **incidence and vascular risk factors in a population-based cohort.** *Neurology* 2013,
894 **80:2112-2120.**

- 895 38. Ganguli M, Chang CC, Snitz BE, Saxton JA, Vanderbilt J, Lee CW: **Prevalence of mild**
896 **cognitive impairment by multiple classifications: The Monongahela-Youghiogheny**
897 **Healthy Aging Team (MYHAT) project.** *Am J Geriatr Psychiatry* 2010, **18**:674-683.
- 898 39. Morris JC: **The Clinical Dementia Rating (CDR): current version and scoring rules.**
899 *Neurology* 1993, **43**:2412-2414.
- 900 40. Kamboh MI, Fan KH, Yan Q, Beer JC, Snitz BE, Wang X, Chang CH, Demirci FY,
901 Feingold E, Ganguli M: **Population-based genome-wide association study of**
902 **cognitive decline in older adults free of dementia: identification of a novel locus**
903 **for the attention domain.** *Neurobiol Aging* 2019, **84**:239.e215-239.e224.
- 904 41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M,
905 Savitcheva I, Huang GF, Estrada S, et al: **Imaging brain amyloid in Alzheimer's**
906 **disease with Pittsburgh Compound-B.** *Ann Neurol* 2004, **55**:306-319.
- 907 42. Lopez OL, Becker JT, Chang Y, Klunk WE, Mathis C, Price J, Aizenstein HJ, Snitz B,
908 Cohen AD, DeKosky ST, et al: **Amyloid deposition and brain structure as long-term**
909 **predictors of MCI, dementia, and mortality.** *Neurology* 2018, **90**:e1920-e1928.
- 910 43. Snitz BE, Tudorascu DL, Yu Z, Campbell E, Lopresti BJ, Laymon CM, Minhas DS,
911 Nadkarni NK, Aizenstein HJ, Klunk WE, et al: **Associations between NIH Toolbox**
912 **Cognition Battery and in vivo brain amyloid and tau pathology in non-demented**
913 **older adults.** *Alzheimers Dement (Amst)* 2020, **12**:e12018.
- 914 44. Baker SL, Maass A, Jagust WJ: **Considerations and code for partial volume**
915 **correcting [(18)F]-AV-1451 tau PET data.** *Data Brief* 2017, **15**:648-657.
- 916 45. Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust
917 WJ: **Comparison of multiple tau-PET measures as biomarkers in aging and**
918 **Alzheimer's disease.** *Neuroimage* 2017, **157**:448-463.
- 919 46. Gogola A, Lopresti BJ, Tudorascu D, Snitz B, Minhas D, Doré V, Ikonovic MD,
920 Shaaban CE, Matan C, Bourgeat P, et al: **Biostatistical Estimation of Tau Threshold**

- 921 **Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.** *Journal of*
922 *Nuclear Medicine* 2023;jnumed.123.265941.
- 923 47. Jack CR, Jr., Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL,
924 Senjem ML, Jones DT, Kantarci K, et al: **Defining imaging biomarker cut points for**
925 **brain aging and Alzheimer's disease.** *Alzheimers Dement* 2017, **13**:205-216.
- 926 48. Benjamini Y, Hochberg Y: **Controlling the False Discovery Rate: A Practical and**
927 **Powerful Approach to Multiple Testing.** *Journal of the Royal Statistical Society: Series*
928 *B (Methodological)* 1995, **57**:289-300.
- 929 49. DeLong ER, DeLong DM, Clarke-Pearson DL: **Comparing the areas under two or**
930 **more correlated receiver operating characteristic curves: a nonparametric**
931 **approach.** *Biometrics* 1988, **44**:837-845.
- 932 50. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M: **pROC: an**
933 **open-source package for R and S+ to analyze and compare ROC curves.** *BMC*
934 *Bioinformatics* 2011, **12**:77.
- 935 51. Goedhart J, Luijsterburg MS: **VolcaNoseR is a web app for creating, exploring,**
936 **labeling and sharing volcano plots.** *Scientific Reports* 2020, **10**:20560.
- 937 52. Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, Lakshmikanth T, Forsström
938 B, Edfors F, Odeberg J, et al: **A genome-wide transcriptomic analysis of protein-**
939 **coding genes in human blood cells.** *Science* 2019, **366**.
- 940 53. Uhlén M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, Zhong W, Tebani A,
941 Strandberg L, Edfors F, et al: **The human secretome.** *Sci Signal* 2019, **12**.
- 942 54. Apte SS, Olsen BR, Murphy G: **The gene structure of tissue inhibitor of**
943 **metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP**
944 **gene family.** *J Biol Chem* 1995, **270**:14313-14318.

- 945 55. Costa S, Ragusa MA, Lo Buglio G, Scilabra SD, Nicosia A: **The Repertoire of Tissue**
946 **Inhibitors of Metalloproteases: Evolution, Regulation of Extracellular Matrix**
947 **Proteolysis, Engineering and Therapeutic Challenges.** *Life* 2022, **12**:1145.
- 948 56. Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S,
949 Rubin JS: **Secreted frizzled-related protein-1 binds directly to Wingless and is a**
950 **biphasic modulator of Wnt signaling.** *J Biol Chem* 2000, **275**:4374-4382.
- 951 57. Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek
952 A, Diehl-Schmid J, Fassbender K, et al: **Chitotriosidase (CHIT1) is increased in**
953 **microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and**
954 **cerebrospinal fluid levels correlate with disease severity and progression.** *J Neurol*
955 *Neurosurg Psychiatry* 2018, **89**:239-247.
- 956 58. Varghese AM, Ghosh M, Bhagat SK, Vijayalakshmi K, Preethish-Kumar V, Vengalil S,
957 Chevula P-C-R, Nashi S, Polavarapu K, Sharma M, et al: **Chitotriosidase, a biomarker**
958 **of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor**
959 **neurons through neuroinflammation.** *Journal of Neuroinflammation* 2020, **17**:232.
- 960 59. Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M,
961 Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, et al: **Distinct cytokine**
962 **profiles in human brains resilient to Alzheimer's pathology.** *Neurobiol Dis* 2019,
963 **121**:327-337.
- 964 60. Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I,
965 Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, et al: **Dissecting**
966 **phenotypic traits linked to human resilience to Alzheimer's pathology.** *Brain* 2013,
967 **136**:2510-2526.
- 968 61. Hwang JY, Zukin RS: **REST, a master transcriptional regulator in neurodegenerative**
969 **disease.** *Curr Opin Neurobiol* 2018, **48**:193-200.

- 970 62. Ren AH, Diamandis EP, Kulasingam V: **Uncovering the Depths of the Human**
971 **Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein**
972 **Detection and Quantification.** *Mol Cell Proteomics* 2021, **20**:100155.
- 973 63. Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE,
974 Cody K, Wilson R, Carlsson CM, et al: **Diagnostic Accuracy of a Plasma**
975 **Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.** *JAMA*
976 *Neurology* 2024, **81**:255-263.
- 977 64. Triana-Baltzer G, Moughadam S, Slemmon R, Van Kolen K, Theunis C, Mercken M,
978 Kolb HC: **Development and validation of a high-sensitivity assay for measuring**
979 **p217+tau in plasma.** *Alzheimer's & Dementia: Diagnosis, Assessment & Disease*
980 *Monitoring* 2021, **13**:e12204.
- 981 65. Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, Kolb HC,
982 Ossenkoppele R, Janelidze S, Hansson O: **Diagnostic and prognostic performance**
983 **to detect Alzheimer's disease and clinical progression of a novel assay for plasma**
984 **p-tau217.** *Alzheimer's Research & Therapy* 2022, **14**:67.
- 985 66. Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G,
986 Snellman A, Schöll M, Troakes C, Hye A, et al: **Plasma p-tau231: a new biomarker for**
987 **incipient Alzheimer's disease pathology.** *Acta Neuropathol* 2021, **141**:709-724.
- 988 67. Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L,
989 Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, et al: **Plasma p-tau231**
990 **and p-tau217 as state markers of amyloid- β pathology in preclinical Alzheimer's**
991 **disease.** *Nature Medicine* 2022, **28**:1797-1801.
- 992 68. Park JH, Cho S-J, Jo C, Park MH, Han C, Kim E-J, Huh GY, Koh YH: **Altered TIMP-3**
993 **Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's**
994 **Disease.** *Journal of Personalized Medicine* 2022, **12**:827.

- 995 69. Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena
996 CM, Pak DT, Cookson MR, Rebeck GW: **The metalloprotease inhibitor TIMP-3**
997 **regulates amyloid precursor protein and apolipoprotein E receptor proteolysis.** *J*
998 *Neurosci* 2007, **27**:10895-10905.
- 999 70. Jia D, Wang F, Yu H: **Systemic alterations of tricarboxylic acid cycle enzymes in**
1000 **Alzheimer's disease.** *Front Neurosci* 2023, **17**:1206688.
- 1001 71. Sonntag K-C, Ryu W-I, Amirault KM, Healy RA, Siegel AJ, McPhie DL, Forester B,
1002 Cohen BM: **Late-onset Alzheimer's disease is associated with inherent changes in**
1003 **bioenergetics profiles.** *Scientific Reports* 2017, **7**:14038.
- 1004 72. Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, Yao XQ, Zhang LL, Zhou HD, Walker
1005 DG, et al: **Brain-derived neurotrophic factor protects against tau-related**
1006 **neurodegeneration of Alzheimer's disease.** *Translational Psychiatry* 2016, **6**:e907-
1007 e907.
- 1008 73. Wojcieszak J, Kuczyńska K, Zawilska JB: **Role of Chemokines in the Development**
1009 **and Progression of Alzheimer's Disease.** *J Mol Neurosci* 2022, **72**:1929-1951.
- 1010 74. Wharton W, Kollhoff AL, Gangishetti U, Verble DD, Upadhya S, Zetterberg H, Kumar V,
1011 Watts KD, Kippels AJ, Gearing M, et al: **Interleukin 9 alterations linked to alzheimer**
1012 **disease in african americans.** *Ann Neurol* 2019, **86**:407-418.
- 1013 75. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: **FGF2 gene transfer restores**
1014 **hippocampal functions in mouse models of Alzheimer's disease and has**
1015 **therapeutic implications for neurocognitive disorders.** *Proc Natl Acad Sci U S A*
1016 2011, **108**:E1339-1348.
- 1017 76. Sathe G, Na CH, Renuse S, Madugundu AK, Albert M, Moghekar A, Pandey A:
1018 **Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate**
1019 **Biomarkers for Alzheimer's Disease.** *PROTEOMICS – Clinical Applications* 2019,
1020 **13**:1800105.

- 1021 77. Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong
1022 DM, Epstein MP, McDade E, et al: **Cerebrospinal fluid proteomics define the natural**
1023 **history of autosomal dominant Alzheimer's disease.** *Nature Medicine* 2023,
1024 **29**:1979-1988.
- 1025 78. Bader JM, Geyer PE, Müller JB, Strauss MT, Koch M, Leypoldt F, Koertvelyessy P,
1026 Bittner D, Schipke CG, Incesoy EI, et al: **Proteome profiling in cerebrospinal fluid**
1027 **reveals novel biomarkers of Alzheimer's disease.** *Molecular Systems Biology* 2020,
1028 **16**:e9356.
- 1029 79. Esteve P, Rueda-Carrasco J, Inés Mateo M, Martin-Bermejo MJ, Draffin J, Pereyra G,
1030 Sardonís Á, Crespo I, Moreno I, Aso E, et al: **Elevated levels of Secreted-Frizzled-**
1031 **Related-Protein 1 contribute to Alzheimer's disease pathogenesis.** *Nat Neurosci*
1032 2019, **22**:1258-1268.
- 1033 80. Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, Yarbro JM, Han X, Lutz BM, Rao S, et al:
1034 **Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's**
1035 **Disease Progression.** *Neuron* 2020, **105**:975-991.e977.
- 1036 81. Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P,
1037 Baiardi S, Zenesini C, Huss A, Cortelli P, et al: **CSF biomarkers of neuroinflammation**
1038 **in distinct forms and subtypes of neurodegenerative dementia.** *Alzheimers Res*
1039 *Ther* 2019, **12**:2.
- 1040 82. Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavado E,
1041 dos Santos AM, Epelbaum S, et al: **Two-level diagnostic classification using**
1042 **cerebrospinal fluid YKL-40 in Alzheimer's disease.** *Alzheimer's & Dementia* 2017,
1043 **13**:993-1003.
- 1044 83. Tubi MA, Kothapalli D, Hapenny M, Feingold FW, Mack WJ, King KS, Thompson PM,
1045 Braskie MN: **Regional relationships between CSF VEGF levels and Alzheimer's**
1046 **disease brain biomarkers and cognition.** *Neurobiol Aging* 2021, **105**:241-251.

- 1047 84. De Kort AM, Kuiperij HB, Kersten I, Versleijen AAM, Schreuder F, Van Nostrand WE,
1048 Greenberg SM, Klijn CJM, Claassen J, Verbeek MM: **Normal cerebrospinal fluid**
1049 **concentrations of PDGFR β in patients with cerebral amyloid angiopathy and**
1050 **Alzheimer's disease.** *Alzheimers Dement* 2022, **18**:1788-1796.
- 1051 85. Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM,
1052 Zetterberg H, Blennow K: **Synaptic proteins in CSF as potential novel biomarkers**
1053 **for prognosis in prodromal Alzheimer's disease.** *Alzheimer's Research & Therapy*
1054 2018, **10**:5.
- 1055 86. Cicognola C, Mattsson-Carlgrén N, van Westen D, Zetterberg H, Blennow K, Palmqvist
1056 S, Ahmadi K, Strandberg O, Stomrud E, Janelidze S, Hansson O: **Associations of CSF**
1057 **PDGFR β With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and**
1058 **Alzheimer Disease Pathologic Changes.** *Neurology* 2023, **101**:e30-e39.
- 1059 87. Wang Y, Emre C, Gyllenhammar-Schill H, Fjellman K, Eyjolfsdottir H, Eriksdotter M,
1060 Schultzberg M, Hjorth E: **Cerebrospinal Fluid Inflammatory Markers in Alzheimer's**
1061 **Disease: Influence of Comorbidities.** *Curr Alzheimer Res* 2021, **18**:157-170.
- 1062 88. Sudduth TL, Winder Z, Elahi FM, Nelson PT, Jicha GA, Wilcock DM: **CSF and plasma**
1063 **placental growth factor as a biomarker for small-vessel damage in VCID.**
1064 *Alzheimer's & Dementia* 2021, **17**:e052995.
- 1065 89. Hinman JD, Elahi F, Chong D, Radabaugh H, Ferguson A, Maillard P, Thompson JF,
1066 Rosenberg GA, Sagare A, Moghekar A, et al: **Placental growth factor as a sensitive**
1067 **biomarker for vascular cognitive impairment.** *Alzheimers Dement* 2023, **19**:3519-
1068 3527.
- 1069 90. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet
1070 AL, Pascoal TA, Lleó A, Parnetti L, et al: **A multicentre validation study of the**
1071 **diagnostic value of plasma neurofilament light.** *Nature Communications* 2021,
1072 **12**:3400.

- 1073 91. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Group atN:
1074 **Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology:**
1075 **A Systematic Review and Meta-analysis.** *JAMA Neurology* 2019, **76**:1035-1048.
- 1076 92. Balistreri CR, Monastero R: **Neuroinflammation and Neurodegenerative Diseases:**
1077 **How Much Do We Still Not Know?** *Brain Sci* 2023, **14**.
- 1078 93. Zhang W, Xiao D, Mao Q, Xia H: **Role of neuroinflammation in neurodegeneration**
1079 **development.** *Signal Transduction and Targeted Therapy* 2023, **8**:267.
- 1080 94. Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV: **Neurovascular dysfunction and**
1081 **neurodegeneration in dementia and Alzheimer's disease.** *Biochim Biophys Acta*
1082 2016, **1862**:887-900.
- 1083 95. Müller N: **The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of**
1084 **Psychiatric Disorders.** *Front Pharmacol* 2019, **10**:1251.
- 1085 96. Otgongerel D, Lee H-J, Jo SA: **Induction of ICAM1 in Brain Vessels is Implicated in**
1086 **an Early AD Pathogenesis by Modulating Neprilysin.** *NeuroMolecular Medicine* 2023,
1087 **25**:193-204.
- 1088 97. Bui TM, Wiesolek HL, Sumagin R: **ICAM-1: A master regulator of cellular responses**
1089 **in inflammation, injury resolution, and tumorigenesis.** *Journal of Leukocyte Biology*
1090 2020, **108**:787-799.
- 1091 98. Lawson C, Wolf S: **ICAM-1 signaling in endothelial cells.** *Pharmacol Rep* 2009, **61**:22-
1092 32.
- 1093 99. Lange C, Storkebaum E, de Almodóvar CR, Dewerchin M, Carmeliet P: **Vascular**
1094 **endothelial growth factor: a neurovascular target in neurological diseases.** *Nature*
1095 *Reviews Neurology* 2016, **12**:439-454.
- 1096 100. Yang H-S, Yau W-YW, Carlyle BC, Trombetta BA, Zhang C, Shirzadi Z, Schultz AP,
1097 Pruzin JJ, Fitzpatrick CD, Kirn DR, et al: **Plasma VEGFA and PGF impact longitudinal**
1098 **tau and cognition in preclinical Alzheimer's disease.** *Brain* 2024.

- 1099 101. Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C: **p62/SQSTM1 at the interface**
1100 **of aging, autophagy, and disease.** *AGE* 2014, **36**:1123-1137.
- 1101 102. Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G,
1102 Calvo A, Gentile S, et al: **SQSTM1 mutations in frontotemporal lobar degeneration**
1103 **and amyotrophic lateral sclerosis.** *Neurology* 2012, **79**:1556-1562.
- 1104 103. Muto V, Flex E, Kupchinsky Z, Primiano G, Galehdari H, Dehghani M, Cecchetti S,
1105 Carpentieri G, Rizza T, Mazaheri N, et al: **Biallelic SQSTM1 mutations in early-onset,**
1106 **variably progressive neurodegeneration.** *Neurology* 2018, **91**:e319-e330.
- 1107 104. Weston LL, Jiang S, Chisholm D, Jantzie LL, Bhaskar K: **Interleukin-10 deficiency**
1108 **exacerbates inflammation-induced tau pathology.** *Journal of Neuroinflammation*
1109 2021, **18**:161.
- 1110 105. Hersh LB, Rodgers DW: **Neprilysin and amyloid beta peptide degradation.** *Curr*
1111 *Alzheimer Res* 2008, **5**:225-231.
- 1112 106. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS: **Neprilysin: An Enzyme**
1113 **Candidate to Slow the Progression of Alzheimer's Disease.** *The American Journal of*
1114 *Pathology* 2008, **172**:1342-1354.
- 1115 107. Campos CR, Kemble AM, Niewoehner J, Freskgård P-O, Urich E: **Brain Shuttle**
1116 **Neprilysin reduces central Amyloid- β levels.** *PLOS ONE* 2020, **15**:e0229850.
- 1117 108. Kim YS, Joh TH: **Matrix metalloproteinases, new insights into the understanding of**
1118 **neurodegenerative disorders.** *Biomol Ther (Seoul)* 2012, **20**:133-143.
- 1119 109. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA,
1120 Lo EH, Montaner J: **Increased Brain Expression of Matrix Metalloproteinase-9 After**
1121 **Ischemic and Hemorrhagic Human Stroke.** *Stroke* 2006, **37**:1399-1406.
- 1122 110. Kwon HS, Koh S-H: **Neuroinflammation in neurodegenerative disorders: the roles**
1123 **of microglia and astrocytes.** *Translational Neurodegeneration* 2020, **9**:42.

- 1124 111. Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH: **Neuroinflammation in**
1125 **Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics.**
1126 *Inflammation* 2023, **46**:1-17.
- 1127







Figure 1**A Detectability****B Intra-plate CV****C Inter-plate CV****D Intra-plate CV by abundance rank****E Inter-plate CV by abundance rank****F Correlation between NULISaseq and Simoa**




Figure 2**A Association between NULISaseq targets and A β PET****B Significant NULISaseq targets**

Figure 3

A A β pathology-dependent longitudinal biomarker change



medRxiv preprint doi: <https://doi.org/10.1101/2024.06.15.24308975>; this version posted June 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

B Baseline biomarker levels vs. yearly A β PET SUVR change





Figure 4

A Cross-sectional association with tau PET



B Tau pathology-dependent longitudinal biomarker change






Figure 5

A NULISaseq targets exhibiting significant univariate association with N status



B Boxplot distributions by N status for selected NULISaseq targets



C Targets with N status-dependent change

